Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP
Corbus Pharmaceuticals — Investor Presentation (November 2017)
45 slides from Corbus Pharmaceuticals's investor presentation, Nov 9, 2017
Slide 1: Developing Breakthrough Therapies for Rare Inflammatory and Fibrotic Diseases
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, bus
Slide 3: Overview
Overview Focus on rare, chronic, serious eteeetete | inflammatory and fibrotic diseases {11 1/4" First-in-class Anabasum | oral synthetic endocannabinoid mimetic Beer Expected Start Phase 3 SSc Study Q4 2017 | (v) Positive Phase 2 data in 3 indications Multiple value-driving milestones expected in Q
Slide 4: Anabasum Pipeline: Multiple Opportunities in Rare Autoimmune / Inflammatory / Fibrotic Diseases
~ Anabasum Pipeline: Multiple Opportunities in Rare Autoimmune / Inflammatory / Fibrotic Diseases Next Catalyst ‘Systemic Sclerosis Plan to commence 30,000 S| 62 |Sa\ 7 |e Ny rises i = Positive Topline ‘Autoimmune Dermatomyositis 70,000 Positive y, GY esis eal (om) (us) Phase 2 mpet | eee ‘Systemic
Slide 5: Normal Inflammatory Process vs. Chronic Inflammation
Normal Inflammatory Process vs. Chronic Inflammation Normal Inflammation Process Inflammatory / Fibrotic Disease ! Chronic Inflammation! Fibrosis Activation Resolution Activation Inflammation / Fibrosis Inflammation / Fibrosis Time Time Immune System Returns to Homeostasis Immune System is Unable to
Slide 6: Anabasum Promotes Resolution of Inflammation and Fibrotic Responses
id Fibrotic Anabasum Promotes Resolution of Inflammatio Responses Resolution of Chronic Inflammation and Fibrosis 2 Activation Fit Inflammation / \ \ \ 1 \ AY \ % ‘=> Homeostasis Time ( MOA Applicable to Multiple Inflammatory / Fibrotic Diseases BO .........__.._._ ree
Slide 7: Endocannabinoids Play a Unique Role in Inflammation
Endocannabinoids Play a Unique Role in Inflammatio MOA of CB2 agonism: triggers resolution of inflammation’ Resolution of Inflammation and Fibrosis Endocannabinoid System CORBUSY
Slide 8: The Endocannabinoid System Has a Dual Role
x The Endocannabinoid System Has a Dual Role * Pain » Nausea * Spasms » Appetite CBI receptors are Immune * Immune System modulation CB2 cacenorsaremosty vin the imine te
Slide 9: Attractive Candidate for Chronic Inflammatory / Fibrotic Diseases
x Attractive Ca ic Inflammatory / Fibrotic Diseases High Low Targeting *CB2 Binding Affinity *CBI1 Binding Affinity Taunecuoprescton Pro-t uti rt themmane syetem) — and Limited CNS *Blood Brain Barrier = |_ Activity + Penetration — CORBUS)y
Slide 10: Diffuse Cutaneous Systemic Sclerosis
Slide 11: Systemic Sclerosis Key Takeaways
Systemic Sclerosis Key Takeaways Chronic systemic autoimmune disease causing fibrosis of skin and internal organs. a 20.000... SNH @ A a Life-threatening, rare disease No SSc-specific drugs approved 80% es es Female patents EET 40-60 Years Average age of patients Current therapy: Immunosuppressive a
Slide 12: Design of Phase 2 Study in Systemic Sclerosis
of Phase 2 Si Des ly Positive Results of Double-blinded, Placebo-controlled Portion of Trial Reported November 2016 2016 9 clinical sites Double- blind across the U.S. randomized, placebo-controlled 43 Adults 16 week study — 12 week active dosing HOTT F 2:1 overat ratio of ne anabasum:placebo map Pr
Slide 13: Safety and Tolerability Summary
x Safety and Tolerability Summary » Anabasum was well tolerated » No serious or severe anabasum-related TEAEs noted » Most common adverse events were mild/moderate: - Dizziness (22% in anabasum-treated subjects vs. 13% in placebo-treated subjects) - Fatigue (19% in anabasum-treated subjects vs. 7% i
Slide 14: mRSS: Skin Thickening Improved
mRSS: Skin Thickening Improved Primary Endpoint in Planned Phase 3 Study mRSS Change from Baseline =e= Anabasum —®= Placebo Change in mRSS, LS means #SE bee How ° 4 8 12 16 44
Slide 15: Improved Patient Reported Skin Symptoms
x Improved Patient Reported Skin Symptoms ‘SSc Skin Symptom Assessment 5-D Itch Questionnaire? 2°] : is 295 1 [- i I 25 H Za ie Bas S00 Pi=00s P=0.008 5 P= 0032 a ° 7 2 ° 2 2 Anabasun “2 Placebo Reduction = improvement ~ Greater improvement in skin symptoms than placebo-treated subjects + Improvemen
Slide 16: Additional Efficacy Outcomes Favor Anabasum
Slide 17: Improvements in ACR-CRISS Scores
Improvements in ACR-CRISS Scores Median ACR CRISS Score P1=0.044 m™ Anabasum (n=26) m Placebo (n= CRISS Score, % Increase = improvement 47. 10.1 sed ed mod sgn sored 2:25 perce, 73h rte
Slide 18: On Target Effect: Anabasum Reduces Inflammation in Skin
On Target Effect: Anabasum Reduces Inflammation in Skin (Histology Analysis) Change in inflammation after only 12 weeks of treatment Placebo Anabasum AmRSS = -1.2 AmRSS =-5.1 Hi Worsened [Unchanged [lj Improved 48
Slide 19: On Target Effect: Anabasum Reduces Fibrosis in Skin
On Target Effect: Anabasum Reduces Fibrosis in Skin (Histology Analysis) Change in fibrosis after only 12 weeks of treatment Placebo Anabasum 46% 43% AmRSS = -1.8 AmRSS = -4.0 Hi Worsened [Unchanged [lj Improved
Slide 20: Ongoing Open-Label Extension - Significant Improvement in mRSS
Ongoing Open-Label Extension - Significant Improvement in mRSS and Other Clinical Outcomes at 28-Weeks Ee. Open Label Extension ——— = Hi 36 Aduts [= Tica ote * Achieved reduction in mRSS of 8.4 points from start of study exceeding clinically important improvement + 75% of subjects achieved degree of
Slide 21: Significant Improvement in mRSS in Open-Label Extension
Demonstrated Significant Improvement in mRSS in Open-Label Extension — Primary Outcome for Upcoming Phase 3 Achieved reduction in mRSS of 8.4 points from start of study (p < 0.0001, 2-side paired t-test) exceeding clinically important improvement (-4.7 points) Double-Blinded Dosing Open-Label Dosing
Slide 22: Improvement in ACR CRISS in Open-Label Extension
Improvement in ACR CRISS in Open-Label Extension ACR CRISS reached 71% (median) from start of study with 44% of subjects achieving a score > 70% Double-Blinded Dosing Open-Label Dosing § a] Sas ea EG a em zo a o Day Wook Wook Weeki Wieek4—~Heok 20 Oay Week Wook 12 Week20_— Weak 6 ‘Tine in Study
Slide 23: Planned Design of Upcoming Phase 3 Study
yi Planned Design of Upcoming Phase 3 Study 23 oui Phase 3 Study Scheduled to Commence Q4 2017 ~ 350 Subjects Multinational Double-blind Ltt randomized, placebo-controlled shot overall ratio of anabasum:placebo _ 3 week study aD - qn ca HHUA STATETURRTETATHHOnaSUT EEE ATUEA TG ‘POTELOPRRENNEPHHTESHT
Slide 24: Cystic Fibrosis
Slide 25: Cystic Fibrosis
25 Cystic Fibrosis CF isa life-threatening, genetic disease that primarily affects the lungs and digestive system. CF is characterized by chronic lung inflammation that leads to lung damage and fibrosis. pecs (1) 75,000 Patients worldwide Hheet #t* 40 Years Average life expectancy of CF patients Key
Slide 26: Pulmonary Exacerbations (PEx)
PEx PULMONARY Cost EXACERBATIONS Dangerous manifestation meen of lung disease wg My, Shortness x of breath, cough, Annual rate sputum production and reduced FEV1 Increased « ») inflammation precedes PEx Irreversable lung function loss, including FEV1 SSS Multiple PEx per year Frequency, severity ~ i
Slide 27: Design of Completed Phase 2 Study
Design of Completed Phase 2 Study Positive Data Announced March 2017 85 Adults 21 clinical sites across Double-blind Ntetelbedgid randomized, lacebo-controed rid - NG siesta = 12 week see sl ThTeTeTierenenenet wt 5:2 overall ratio “Y of anabasum:placebo Primary Objectives: Secondary Objet Evaicte ea
Slide 28: Safety and Tolerability Summary
Safety and Tolerability Summary » Anabasum was well tolerated - No serious or severe anabasum-related TEAEs noted » Most common anabasum-related mild adverse event: - Dry mouth (mild, 13% vs 0% in placebo) » FEV-1 remained stable throughout the study across all cohorts 28 eee
Slide 29: Anabasum Increases Time to First New Pulmonary Exacerbations
Anabasum Increases Time to First New Pulmonary Exacerbations Treated with Oral or IV Antibiotics " - 7 i Time to First PEx: Negative Log of Kaplan-Meier Survival Time Without a PEx ‘Survival Time without PEx zg s Placebo. Zo Bos i i “ g Anabasum, —— P = 0.047, Cox proportional hazard model, 2-sided,
Slide 30: Consistent Reduction in Key Inflammatory Biomarkers (Sputum)
x Consistent Reduction in Key Inflammatory Biomarkers (Sputum) Reduction with anabasum 20 mg BID compared to placebo (Log,,) Neutrophils, cells/ml | Eosinophils, cells/ml Lymphocytes, cells/ml Macrophages, cells/m! pr0oss—_________f "as p= 0.089 0.23 | Neutrophil elastase, cells/ml [foa9] IL-8, pg/m
Slide 31: Dermatomyositis
Dermatomyositis: 31 Positive Phase 2 data Late-breaking data presented at ACR Ongoing open-label extension CORBUS PHARMACEUTICALS
Slide 32: Dermatomyositis
32 Dermatomyositis Chronic systemic autoimmune disease characterized by inflammation of skin and muscles Ceo neus.cu MACE Skin & Muscle Involvement can cause significant morbidity and mortality from interstitial lung disease No FDA Approved therapies for overall disease activity Key Takeaways Treate
Slide 33: Dermatomyositis Phase 2 Clinical Study
Dermatomyositis Phase 2 Clinical Study ‘ive Data Announced November 2017 Perelman School of Medicine randomized, placebo-controlled at L 16 week study 12 week active dosing 22 Adults 1 Site ~ eared Double-blind : > 7 1:1 oral ratio of 2 - S@D- anabasum:placebo s [pas RY [oma J Secondary Endpoints: P
Slide 34: Safety and Tolerability Summary
x Safety and Tolerability Summary » Anabasum was well tolerated and demonstrated a favorable safety profile » No evidence of immunosuppression » No serious or severe side effects related to anabasum » No subjects dropped out of the study CORBUS)y
Slide 35: Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) CDASI was developed to measure multiple inflammatory elements in the skin’ Disease Severity Measurement Location scar PERIORBITAL OMALAR AREA restortuerace. | 4 3 POSTERIOR NECK AREA NECK (FRONTAL) UPPER BACK & SHOULDERS, ARM, REST OF
Slide 36: CDASI Score — Anabasum Demonstrated Clinically Meaningful Improvement
CDASI Score — Anabasum Demonstrated Clinically Meaningful Improvement Anabasum improved CDASI by 9.3 vs. 3.7 for placebo; p = 0.04, 2-sided MMRM. Mean Change from Day 1 (SE) -e-Anabasum -@-Placebo o 2 4 6 8 wm 2 we 6 Weeks Completed [20mgan Y20mgsi Post Ps = 66, MR bar Po cng me 36
Slide 37: Additional Efficacy Outcomes Favor Anabasum
Slide 38: Strong Evidence of Clinical Benefit Merits Further Development
x Strong Evidence of Clinical Benefit Merits Further Develop Dermatomyo: + First potential treatment for skin-predominant dermatomyositis to show clinical benefit in a double-blind, randomized, placebo-controlled trial » Will meet with regulatory authorities to review data and determine next steps i
Slide 39: Management Team
" Management Team ‘Yuval Cohen, PhD. Chief Executive Officer, Director Co-founder and former President of Celsus ‘Therapeutics (CLTX). Expertise in developing ant.inflammatory drugs including for CF ‘Sean Moran, CPA, MBA Chief Financial Officer Former CFO: InVivo (NVIV), Celsion (CLSN), ‘Transport P
Slide 40: Board of Directors
Board of Directors 40 ‘Amb, Alan Holmer Ret.-Chaieman of the Board + Former CEO of PhRMA (1996-2005) + Over two decades of public service in Washington, D.C. including Special Envoy to China (2007-2008) + Former board member o Inspire Pharma + Chaiman of the Board ofthe Metropolitan Washington, 1. C
Slide 41: Scientific Advisory and Principal Investigators
Scientific Advisory and Principal Investigators Scientific Advisors Principal Investigators Michael Knowles, MD D puscicncces Robert Spera, MD Ra Ose FoR ene nose SPECIAL HARVARD Christopher Denton, PhD, FRCP Charles Serhan, PhD. MEDICAL SCHOOL Royal Free London [MEE EUPI~SSc verte 44 James Chmiel,
Slide 42: Expected Milestones in Q4 2017
42 ~ Expected Milestones in Q4 2017 2017 ——_ SSc SLE Launch Phase 3 study ||} Expected launch of Phase 2b study Reported positive topline Phase 2 [i Start Phase 2 study Interim data from open-label study Phase 2 data to be data presented at Phase 2 Data to be NACFC-17 presented at ACR-17, CORBUSY
Slide 43: Financial Profile: CRBP (NASDAQ)
yi Financial Profile: CRBP (NASDAQ) $115MM 54.9MM | Pasos oat $376MM || conmonsnaes | “|| 740K || samo + Market cap* ‘outstanding $20MM daily volume" Cash balance** (639MM fully diuted)** Pnveennien NIH. ang CF Foundation
Slide 44: Focused on rare diseases with no current approved therapies
Focused on rare diseases with no current approved therapies - First-in-class drug targeting inflammation + fibrosis Ha Positive Phase 2 data in 3 indications 7 | Solid execution with multiple milestones expected in Q4 2017
Slide 45: Contact Us
x CONTACT US Corbus Pharmaceuticals Holdings, Inc. 617.963.0100 corbuspharma.com www.corbuspharma.com 100 River Ridge Drive Norwood, MA 02062
Corbus Pharmaceuticals Holdings — Investor Presentation (November 2017) on 6ix